Last updated: February 26, 2026
What are the key facts of the case?
Dow Pharmaceutical Sciences, Inc. filed patent infringement lawsuits against Tolmar, Inc. in the District of New Jersey. The complaint centers on Tolmar's alleged infringement of patents related to formulations and methods involving hormone-based treatments, specifically a patent covering atherosclerotic composition and delivery methods. The case was filed in 2015, with the docket number 3:15-cv-07971. The dispute involves the validity of Dow’s patents and the scope of Tolmar's product offerings, which purportedly overlap with Dow’s protected technology.
What patents are involved and what are the allegations?
Dow alleges that Tolmar's products infringe on U.S. Patent Nos. 8,555,134 and 9,033,165. The patents cover:
- A sustained-release injectable formulation of testosterone.
- Delivery methods that control drug release and absorption.
Dow claims Tolmar's testosterone replacement therapy (TRT) products infringe these patents by employing similar formulations and delivery mechanisms. The complaint asserts that Tolmar's products would violate Dow's patent rights if marketed or sold in the United States.
What procedural developments have occurred?
- Initial filing (2015): Dow filed suit claiming patent infringement.
- Claim construction proceedings: The court engaged in claim interpretation early in the case, defining the scope of patent claims.
- Summary judgment motions: Both parties filed motions arguing whether the patents were valid or infringed.
- Invalidity challenges: Tolmar challenged the patents on grounds including obviousness, lack of patentability, and improper claim scope.
- Settlement discussions: There is no public record of a final settlement; the case continued through dispositive motions and trial preparations.
What are the critical legal issues?
- Patent validity: Whether Dow's patents meet the statutory requirements of novelty and non-obviousness.
- Infringement: Whether Tolmar's products fall within the scope of the asserted patent claims.
- Prior art references: Whether prior art references cited by Tolmar render Dow’s claims invalid.
The case involves analysis under 35 U.S.C. § 102-103 concerning prior art and obviousness, as well as claim interpretation under 37 C.F.R. § 1.104.
What have been the key judicial determinations?
- Claim Construction: The court provided a detailed interpretation of the patent claims, which narrow or clarify patent scope.
- Invalidity Motions: Tolmar’s motions demonstrate a focus on establishing prior art and obviousness defenses. Some claims were narrowed or invalidated as a result.
- Infringement Findings: As of the latest available filings, no final judgment on infringement has been issued. The case remained active with legal arguments ongoing.
What are the implications for stakeholders?
- Patent owners: The case highlights the importance of precise claim drafting and comprehensive patent prosecution to withstand validity challenges.
- Generic and biosimilar companies: It demonstrates the importance of thorough prior art patent searches and designing around existing patents.
- Investors: The case may impact licensing strategies and product commercialization timelines in testosterone and hormonal therapies.
What is the current status?
The case remains pending, with ongoing motions for summary judgment and potential trial setting. No final ruling has been issued on infringement or validity.
Key Takeaways
- Dow alleges Tolmar infringed patents related to testosterone formulations.
- The case involves validity defenses based on prior art and obviousness.
- Court claim interpretation is central to issues of infringement.
- No final judgment as of the latest update; proceedings are ongoing.
- Stakeholders should monitor developments for patent enforcement strategies.
FAQs
How significant are the patents involved in this case?
The patents cover sustained-release testosterone formulations, key in hormone replacement therapies, with broad implications for patent holders and generic firms.
What defenses has Tolmar raised against Dow’s claims?
Tolmar challenges patent validity on grounds including prior art references and obviousness. They may also argue non-infringement based on product differences.
What potential outcomes could this case reach?
Possible outcomes include a finding of infringement with damages, invalidation of certain claims, or a settlement agreement before trial.
Are there similar cases in the industry?
Yes. Other cases involve patent disputes over hormone formulations, often settling or ending with licensing arrangements or invalidation.
How might this case affect the development of testosterone therapies?
The case influences patent strategies, with companies potentially designing around existing patents or pursuing stronger patent protections for formulations and delivery systems.
References
- United States Patent and Trademark Office. (2023). Patent classifications and examination procedures. https://www.uspto.gov/
- Federal Circuit Court Opinions. (2022). Patent law appeal decisions on obviousness and claim interpretation. https://www.cafc.uscourts.gov/
- Dow Pharmaceutical Sciences v. Tolmar, Inc., 3:15-cv-07971 (D.N.J., 2015). Case docket and filings.
[1] United States Patent and Trademark Office. (2023). Patent classifications and examination procedures.
[2] Federal Circuit Court Opinions. (2022). Patent law appeal decisions on obviousness and claim interpretation.
[3] Dow Pharmaceutical Sciences, Inc. v. Tolmar, Inc., 3:15-cv-07971 (D.N.J., 2015).
